PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites
NCT ID: NCT00561327
Last Updated: 2007-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
OBSERVATIONAL
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Angiotensin II receptor 1-blocking and PPAR-γ-activating properties of losartan metabolites in patients would markedly improve the pharmacological profile of losartan by combining anti-hypertensive and highly beneficial metabolic actions. We developed the following hypothesis:
1. Hypertensive patients chronically treated with losartan exhibit sufficient plasma levels of EXP3179 to activate PPARγ.
2. PPARγ target genes are induced in monocytes from losartan-treated patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Patients chronically treated with drug losartan
losartan
Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
B
Patients not chronically treated with losartan
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
losartan
Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sex: male or female
* Prior diagnosis of treated hypertension
* Treatment with losartan 100mg/daily during at least the past 2 months (n=20/ case);
* or: no prior angiotensin receptor 1-blocker treatment during the last 2 months (n=10/ control).
Exclusion Criteria
* Therapy with glitazones for the past 21 days.
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
German Heart Institute
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eckart Fleck, Prof
Role: PRINCIPAL_INVESTIGATOR
German Heart Institute
Ulrich Kintscher, Prof
Role: PRINCIPAL_INVESTIGATOR
Institute of Pharmacology Charite University Medicine Berlin Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
German Heart Institute
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eckart Fleck, Prof
Role: primary
Philipp Stawowy, Dr
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P2132V1
Identifier Type: -
Identifier Source: org_study_id